NF-κB in cancer therapy

Archives of Toxicology

Volumn 89, Issue 5, 2015, Pages 711-731

  Li, Feng ^a   Zhang, Jingwen ^a   Arfuso, Frank ^b   Chinnathambi, Arunachalam ^c   Zayed, M E ^c   Alharbi, Sulaiman Ali ^c   Kumar, Alan Prem ^a,b,d,e   Ahn, Kwang Seok ^f   Sethi, Gautam ^a,b,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b CURTIN UNIVERSITY   (Australia)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e UNIVERSITY OF NORTH TEXAS   (United States)

^f Kyung Hee University   (South Korea)

Author keywords

Angiogenesis; Apoptosis; Cancer; NF B; Proliferation

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANIMAL; DRUG EFFECTS; HUMAN; NEOPLASMS; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 84939967245     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-015-1470-4     Document Type: Review

References (270)

1. Adams J (2004) The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4(5):349–360. doi:10.1038/Nrc1361
2. Aggarwal BB (2004) Nuclear factor-kappa-B: the enemy within. Cancer Cell 6(3):203–208. doi:10.1016/j.ccr.2004.09.003
3. Aggarwal BB, Shishodia S (2006) Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71(10):1397–1421. doi:10.1016/j.bcp.2006.02.009
4. Aktas O, Prozorovski T, Smorodchenko A et al (2004) Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J Immunol 173(9):5794–5800
5. Albanese C, Wu KM, D’Amico M et al (2003) IKK alpha regulates mitogenic signaling through transcriptional induction of cyclin D1 via Tcf. Mol Biol Cell 14(2):585–599. doi:10.1091/mbc.02-06-0101
6. Allen CT, Ricker JL, Chen Z, Van Waes C (2007) Role of activated nuclear factor-kappa B in the pathogenesis and therapy of squamous cell carcinoma of the head and neck. Head Neck J Sci Spec 29(10):959–971. doi:10.1002/Hed.20615
7. Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M (2010) B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 464(7286):302–305. doi:10.1038/Nature08782
8. Anderson KC, Carrasco RD (2011) Pathogenesis of myeloma. Annu Rev Pathol Mech 6:249–274. doi:10.1146/annurev-pathol-011110-130249
9. Annunziata CM, Davis RE, Demchenko Y et al (2007) Frequent engagement of the classical and alternative NF-kappa B pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12(2):115–130. doi:10.1016/j.ccr.2007.07.004
10. Anto RJ, Mukhopadhyay A, Shishodia S, Gairola CG, Aggarwal BB (2002) Cigarette smoke condensate activates nuclear transcription factor-kappa B through phosphorylation and degradation of I kappa B alpha: correlation with induction of cyclooxygenase-2. Carcinogenesis 23(9):1511–1518. doi:10.1093/carcin/23.9.1511
11. Arber N, Doki Y, Han EKH et al (1997) Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res 57(8):1569–1574
12. Arsura M, Cavin LG (2005) Nuclear factor-kappaB and liver carcinogenesis. Cancer Lett 229(2):157–169. doi:10.1016/j.canlet.2005.07.008
13. Arsura M, Mercurio F, Oliver AL, Thorgeirsson SS, Sonenshein GE (2000) Role of the I kappa B kinase complex in oncogenic Ras- and Raf-mediated transformation of rat liver epithelial cells. Mol Cell Biol 20(15):5381–5391. doi:10.1128/Mcb.20.15.5381-5391.2000
14. Arsura M, Panta GR, Bilyeu JD et al (2003) Transient activation of NF-kappa B through a TAK1/IKK kinase pathway by TGF-beta 1 inhibits AP-1/SMAD signaling and apoptosis: implications in liver tumor formation. Oncogene 22(3):412–425. doi:10.1038/sj.onc.1206132
15. Asano T, Yao YX, Zhu JJ, Li DH, Abbruzzese JL, Reddy SAG (2004) The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappa B and c-Myc in pancreatic cancer cells. Oncogene 23(53):8571–8580. doi:10.1038/sj.onc.1207902
16. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M (1995) Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270(5234):286–290
17. Baldwin AS (1996) The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 14:649–683. doi:10.1146/annurev.immunol.14.1.649
18. Baldwin AS (2012) Regulation of cell death and autophagy by IKK and NF-kappa B: critical mechanisms in immune function and cancer. Immunol Rev 246:327–345. doi:10.1111/j.1600-065X.2012.01095.x
19. Bancroft CC, Chen Z, Dong G et al (2001) Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kappaB signal pathways. Clin Cancer Res 7(2):435–442
20. Bancroft CC, Chen Z, Yeh J et al (2002) Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 99(4):538–548. doi:10.1002/ijc.10398
21. Bargou RC, Emmerich F, Krappmann D et al (1997) Constitutive nuclear factor-kappa B-RelA activation is required for proliferation and survival of Hodgkin’s disease tumor cells. J Clin Invest 100(12):2961–2969. doi:10.1172/Jci119849
22. Baron JA, Cole BF, Sandler RS et al (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348(10):891–899. doi:10.1056/NEJMoa021735
23. Basseres DS, Baldwin AS (2006) Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 25(51):6817–6830. doi:10.1038/sj.onc.1209942
24. Biswas DK, Shi Q, Baily S et al (2004) NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci USA 101(27):10137–10142. doi:10.1073/pnas.0403621101
25. Block TM, Mehta AS, Fimmel CJ, Jordan R (2003) Molecular viral oncology of hepatocellular carcinoma. Oncogene 22(33):5093–5107. doi:10.1038/sj.onc.1206557
26. Bollrath J, Greten FR (2009) IKK/NF-kappa B and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep 10(12):1314–1319. doi:10.1038/embor.2009.243
27. Bonizzi G, Karin M (2004) The two NF-kappa B activation pathways and their role in innate and adaptive immunity. Trends Immunol 25(6):280–288. doi:10.1016/J.It.2004.03.008
28. Bouchard MJ, Schneider RJ (2004) The enigmatic X gene of hepatitis B virus. J Virol 78(23):12725–12734. doi:10.1128/Jvi.78.23.12725-12734.2004
29. Burke JR, Pattoli MA, Gregor KR et al (2003) BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. J Biol Chem 278(3):1450–1456. doi:10.1074/jbc.M209677200
30. Cao YX, Bonizzi G, Seagroves TN et al (2001) IKK alpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell 107(6):763–775. doi:10.1016/S0092-8674(01)00599-2
31. Cao YX, Luo JL, Karin M (2007) I kappa B kinase a kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells. Proc Natl Acad Sci USA 104(40):15852–15857. doi:10.1073/pnas.0706728104
32. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407(6801):249–257. doi:10.1038/35025220
33. Carrasco D, Rizzo CA, Dorfman K, Bravo R (1996) The v-rel oncogene promotes malignant T-cell leukemia/lymphoma in transgenic mice. EMBO J 15(14):3640–3650
34. Castro AC, Dang LC, Soucy F et al (2003) Novel IKK inhibitors: beta-carbolines. Bioorg Med Chem Lett 13(14):2419–2422. doi:10.1016/S0960-894x(03)00408-6
35. Catz SD, Johnson JL (2001) Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 20(50):7342–7351. doi:10.1038/sj.onc.1204926
36. Cavin LG, Wang F, Factor VM et al (2005) Transforming growth factor-alpha inhibits the intrinsic pathway of c-myc-induced apoptosis through activation of nuclear factor-kappa B in murine hepatocellular carcinomas. Mol Cancer Res 3(7):403–412. doi:10.1158/1541-7786.Mcr-04-0186
37. Chang F, Steelman LS, Lee JT et al (2003) Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 17(7):1263–1293. doi:10.1038/sj.leu.2402945
38. Chen LF, Greene WC (2004) Shaping the nuclear action of NF-kappa B. Nat Rev Mol Cell Bio 5(5):392–401. doi:10.1038/Nrm1368
39. Chen CL, Edelstein LC, Gelinas C (2000) The Rel/NF-kappa B family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 20(8):2687–2695. doi:10.1128/Mcb.20.8.2687-2695.2000
40. Chu ZL, McKinsey TA, Liu L, Gentry JJ, Malim MH, Ballard DW (1997) Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappa B control. Proc Natl Acad Sci USA 94(19):10057–10062. doi:10.1073/pnas.94.19.10057
41. Chung CH, Parker JS, Ely K et al (2006) Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappa B signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res 66(16):8210–8218. doi:10.1158/0008-5472.Can-06-1213
42. Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin AS (2000) Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene 19(9):1123–1131. doi:10.1038/sj.onc.1203412
43. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T (1995) Transcriptional regulation of endothelial-cell adhesion molecules—Nf-Kappa-B and cytokine-inducible enhancers. Faseb J 9(10):899–909
44. Courtois G, Gilmore TD (2006) Mutations in the NF-kappaB signaling pathway: implications for human disease. Oncogene 25(51):6831–6843. doi:10.1038/sj.onc.1209939
45. Cusack JC, Liu R, Houston M et al (2001) Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappa B inhibition. Cancer Res 61(9):3535–3540
46. Dan HC, Cooper MJ, Cogswell PC, Duncan JA, Ting JPY, Baldwin AS (2008) Akt-dependent regulation of NF-kappa B is controlled by mTOR and raptor in association with IKK. Genes Dev 22(11):1490–1500. doi:10.1101/Gad.1662308
47. Dandekar DS, Lopez M, Carey RI, Lokeshwar BL (2005) Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and-9 in prostate cancer cells. Int J Cancer 115(3):484–492. doi:10.1002/Ijc.20878
48. Davis RE, Brown KD, Siebenlist U, Staudt LM (2001) Constitutive nuclear factor kappa B activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 194(12):1861–1874. doi:10.1084/jem.194.12.1861
49. De Smaele E, Zazzeroni F, Papa S et al (2001) Induction of gadd45 beta by NF-kappa B downregulates pro-apoptotic JNK signalling. Nature 414(6861):308–313. doi:10.1038/35104560
50. Demchenko YN, Glebov OK, Zingone A, Keats JJ, Bergsagel PL, Kuehl WM (2010) Classical and/or alternative NF-kappa B pathway activation in multiple myeloma. Blood 115(17):3541–3552. doi:10.1182/blood-2009-09-243535
51. Deveraux QL, Reed TC (1999) IAP family proteins—suppressors of apoptosis. Genes Dev 13(3):239–252. doi:10.1101/Gad.13.3.239
52. Dhillon N, Aggarwal BB, Newman RA et al (2008) Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14(14):4491–4499. doi:10.1158/1078-0432.Ccr-08-0024
53. Diao JY, Garces R, Richardson CD (2001) X protein of hepatitis B virus modulates cytokine and growth factor related signal transduction pathways during the course of viral infections and hepatocarcinogenesis. Cytokine Growth Fact Rev 12(2–3):189–205. doi:10.1016/S1359-6101(00)00034-4
54. Dikshit P, Goswami A, Mishra A, Chatterjee M, Jana NR (2006) Curcumin induces stress response, neurite outgrowth and prevent NF-kappa B activation by inhibiting the proteasome function. Neurotox Res 9(1):29–37
55. Dong G, Loukinova E, Chen Z et al (2001) Molecular profiling of transformed and metastatic murine squamous carcinoma cells by differential display and cDNA microarray reveals altered expression of multiple genes related to growth, apoptosis, angiogenesis, and the NF-kappaB signal pathway. Cancer Res 61(12):4797–4808
56. Donnellan R, Chetty R (1998) Cyclin D1 and human neoplasia. J Clin Pathol Mol Pathol 51(1):1–7
57. Du J, Chen GG, Vlantis AC, Xu H, Tsang RKY, van Hasselt AC (2003) The nuclear localization of NF kappa B and p53 is positively correlated with HPV16 E7 level in laryngeal squamous cell carcinoma. J Histochem Cytochem 51(4):533–539
58. Duffey DC, Chen Z, Dong G et al (1999) Expression of a dominant-negative mutant inhibitor-kappaBalpha of nuclear factor-kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res 59(14):3468–3474
59. Dunleavy K, Pittaluga S, Czuczman MS et al (2009) Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 113(24):6069–6076. doi:10.1182/blood-2009-01-199679
60. Farah M, Parhar K, Moussavi M, Eivemark S, Salh B (2003) 5,6-Dichloro-ribifuranosylbenzimidazole- and apigenin-induced sensitization of colon cancer cells to TNF-alpha-mediated apoptosis. Am J Physiol Gastrointest Liver Physiol 285(5):G919–G928. doi:10.1152/ajpgi.00205.2003
61. Finco TS, Westwick JK, Norris JL, Beg AA, Der CJ, Baldwin AS (1997) Oncogenic Ha-Ras-induced signaling activates NF-kappa B transcriptional activity, which is required for cellular transformation. J Biol Chem 272(39):24113–24116. doi:10.1074/jbc.272.39.24113
62. Fosslien E (2000) Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Cl Lab Sci 37(5):431–502. doi:10.1080/10408360091174286
63. Fradet V, Lessard L, Begin LR, Karakiewicz P, Masson AMM, Saad F (2004) Nuclear factor-kappa B nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. Clin Cancer Res 10(24):8460–8464. doi:10.1158/1078-0432.Ccr-04-0764
64. Fujioka S, Niu J, Schmidt C et al (2004) NF-kappaB and AP-1 connection: mechanism of NF-kappaB-dependent regulation of AP-1 activity. Mol Cell Biol 24(17):7806–7819. doi:10.1128/MCB.24.17.7806-7819.2004
65. Gasparian AV, Yao YJ, Kowalczyk D et al (2002) The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J Cell Sci 115(Pt 1):141–151
66. Ghosh S, May MJ, Kopp EB (1998) NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16:225–260. doi:10.1146/annurev.immunol.16.1.225
67. Gilmore TD (1999) Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel. Oncogene 18(49):6925–6937. doi:10.1038/sj.onc.1203222
68. Gilmore TD, Kalaitzidis D, Liang MC, Starczynowski DT (2004) The c-Rel transcription factor and B-cell proliferation: a deal with the devil. Oncogene 23(13):2275–2286. doi:10.1038/sj.onc.1207410
69. Glaser R, Ogino T, Zimmerman J Jr, Rapp F (1973) Thymidine kinase activity in Burkitt lymphoblastoid somatic cell hybrids after induction of the EB virus. Proc Soc Exp Biol Med 142(4):1059–1062
70. Greten FR, Eckmann L, Greten TF et al (2004) IKK beta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118(3):285–296. doi:10.1016/j.cell.2004.07.013
71. Grivennikov SI, Karin M (2010) Dangerous liaisons: STAT3 and NF-kappa B collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 21(1):11–19. doi:10.1016/j.cytogfr.2009.11.005
72. Guha M, Mackman N (2001) LPS induction of gene expression in human monocytes. Cell Signal 13(2):85–94. doi:10.1016/S0898-6568(00)00149-2
73. Guo J, Verma UN, Gaynor RB, Frenkel EP, Becerra CR (2004) Enhanced chemosensitivity to irinotecan by RNA interference mediated down-regulation of the nuclear factor-kappa B p65 subunit. Clin Cancer Res 10(10):3333–3341. doi:10.1158/1078-0432.Ccr-03-0366
74. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS (1999) NF-kappa B controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 19(8):5785–5799
75. Gyrd-Hansen M, Meier P (2010) IAPs: from caspase inhibitors to modulators of NF-kappa B, inflammation and cancer. Nat Rev Cancer 10(8):561–574. doi:10.1038/Nrc2889
76. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. doi:10.1016/j.cell.2011.02.013
77. Hanson JL, Hawke NA, Kashatus D, Baldwin AS (2004) The nuclear factor kappa B subunits RelA/p65 and c-Rel potentiate but are not required for Ras-induced cellular transformation. Cancer Res 64(20):7248–7255. doi:10.1158/0008-5472.Can-03-3898
78. Hardwick JCH, van den Brink GR, Offerhaus GJ, van Deventer SJH, Peppelenbosch MP (2001) NF-kappaB, p38 MAPK and JNK are highly expressed and active in the stroma of human colonic adenomatous polyps. Oncogene 20(7):819–827. doi:10.1038/sj.onc.1204162
79. Hayden MS, Ghosh S (2004) Signaling to NF-kappa B. Genes Dev 18(18):2195–2224. doi:10.1101/Gad.1228704
80. Hayden MS, Ghosh S (2008) Shared principles in NF-kappa B signaling. Cell 132(3):344–362. doi:10.1016/j.cell.2008.01.020
81. Helbig G, Christopherson KW, Bhat-Nakshatri P et al (2003) NF-kappa B promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 278(24):21631–21638. doi:10.1074/jbc.M300609200
82. Herr I, Debatin KM (2001) Cellular stress response and apoptosis in cancer therapy. Blood 98(9):2603–2614. doi:10.1182/blood.V98.9.2603
83. Herrmann JL, Beham AW, Sarkiss M et al (1997) Bcl-2 suppresses apoptosis resulting from disruption of the NF-kappa B survival pathway. Exp Cell Res 237(1):101–109. doi:10.1006/excr.1997.3737
84. Hershko A, Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67:425–479. doi:10.1146/annurev.biochem.67.1.425
85. Hideshima T, Chauhan D, Richardson P et al (2002) NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277(19):16639–16647. doi:10.1074/jbc.M200360200
86. Hideshima T, Mitsiades C, Akiyama M et al (2003) Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101(4):1530–1534. doi:10.1182/blood-2002-08-2543
87. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC (2004) Advances in biology of multiple myeloma: clinical applications. Blood 104(3):607–618. doi:10.1182/blood-2004-01-0037
88. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M (1999) NF-kappa B function in growth control: regulation of cyclin D1 expression and G(0)G(1)-to-S-Phase transition. Mol Cell Biol 19(4):2690–2698
89. Hjarnaa PJV, Jonsson E, Latini S et al (1999) CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo. Cancer Res 59(22):5751–5757
90. Hodge DR, Hurt EM, Farrar WL (2005) The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 41(16):2502–2512. doi:10.1016/j.ejca.2005.08.016
91. Hofer-Warbinek R, Schmid JA, Stehlik C, Binder BR, Lipp J, de Martin R (2000) Activation of NF-kappa B by XIAP, the X chromosome-linked inhibitor of apoptosis, in endothelial cells involves TAK1. J Biol Chem 275(29):22064–22068. doi:10.1074/jbc.M910346199
92. Hovstadius P, Larsson R, Jonsson E et al (2002) A phase I study of CHS 828 in patients with solid tumor malignancy. Clin Cancer Res 8(9):2843–2850
93. Huang S, DeGuzman A, Bucana CD, Fidler IJ (2000a) Nuclear factor-kappa B activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice. Clin Cancer Res 6(6):2573–2581
94. Huang S, Robinson JB, DeGuzman A, Bucana CD, Fidler IJ (2000b) Blockade of nuclear factor-kappa B signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res 60(19):5334–5339
95. Huang SY, Pettaway CA, Uehara H, Bucana CD, Fidler IJ (2001) Blockade of NF-kappa B activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20(31):4188–4197. doi:10.1038/sj.onc.1204535
96. Huber MA, Azoitei N, Baumann B et al (2004) NF-kappa B is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 114(4):569–581. doi:10.1172/Jci200421358
97. Hunter T, Pines J (1994) Cyclins and cancer. 2. Cyclin-D and Cdk inhibitors come of age. Cell 79(4):573–582. doi:10.1016/0092-8674(94)90543-6
98. Hunter AM, LaCasse EC, Korneluk RG (2007) The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 12(9):1543–1568. doi:10.1007/s10495-007-0087-3
99. Ismail H, Lessard L, Mes-Masson AM, Saad F (2004) Expression of NF-kappa B in prostate cancer lymph node metastases. Prostate 58(3):308–313. doi:10.1002/Pros.10335
100. Jackson-Bernitsas DG, Ichikawa H, Takada Y et al (2007) Evidence that TNF-TNFR1-TRADD-TRAF2-RIP-TAK1-IKK pathway mediates constitutive NF-kappa B activation and proliferation in human head and neck squamous cell carcinoma. Oncogene 26(10):1385–1397. doi:10.1038/sj.onc.1209945
101. Jost PJ, Ruland J (2007) Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 109(7):2700–2707. doi:10.1182/blood-2006-07-025809
102. Jung YJ, Isaacs JS, Lee SM, Trepel J, Neckers L (2003) IL-1 beta mediated up-regulation of HIF-1 alpha via an NFkB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. Faseb J 17(12):2115–2117. doi:10.1096/fj.03-0329fje
103. Jurenka JS (2009) Anti-inflammatory properties of curcumin, a major constituent of curcuma longa: a review of preclinical and clinical research. Altern Med Rev 14(2):141–153
104. Kamata H, Honda S, Maeda S, Chang LF, Hirata H, Karin M (2005) Reactive oxygen species promote TNF alpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 120(5):649–661. doi:10.1016/j.cell.2004.12.041
105. Kane LP, Mollenauer MN, Xu Z, Turck CW, Weiss A (2002) Akt-dependent phosphorylation specifically regulates Cot induction of NF-kappa B-dependent transcription. Mol Cell Biol 22(16):5962–5974. doi:10.1128/Mcb.22.16.5962-5974.2002
106. Kane RC, Bross PF, Farrell AT, Pazdur R (2003) Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 8(6):508–513
107. Karin M (2006) Nuclear factor-kappa B in cancer development and progression. Nature 441(7092):431–436. doi:10.1038/Nature04870
108. Karin M, Lin A (2002) NF-kappa B at the crossroads of life and death. Nat Immunol 3(3):221–227. doi:10.1038/Ni0302-221
109. Karin M, Cao Y, Greten FR, Li ZW (2002) NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2(4):301–310. doi:10.1038/nrc780
110. Karin M, Yamamoto Y, Wang QM (2004) The IKKNF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 3(1):17–26. doi:10.1038/Nrd1279
111. Kawakami H, Tomita M, Matsuda T et al (2005) Transcriptional activation of survivin through the NF-kappa B pathway by human T-cell leukemia virus type I Tax. Int J Cancer 115(6):967–974. doi:10.1002/Ijc.20954
112. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N (1998) Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58(22):5071–5074
113. Keats JJ, Fonseca R, Chesi M et al (2007) Promiscuous mutations activate the noncanonical NF-kappa B pathway in multiple myeloma. Cancer Cell 12(2):131–144. doi:10.1016/j.ccr.2007.07.003
114. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr (2001) Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 276(25):22382–22387. doi:10.1074/jbc.M100938200
115. Kim I, Moon SO, Kim SH, Kim HJ, Koh YS, Koh GY (2001) Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem 276(10):7614–7620. doi:10.1074/jbc.M009705200
116. Kim BY, Gaynor RB, Song K, Dritschilo A, Jung M (2002) Constitutive activation of NF-kappaB in Ki-ras-transformed prostate epithelial cells. Oncogene 21(29):4490–4497. doi:10.1038/sj.onc.1205547
117. Kirchner D, Duyster J, Ottmann O, Schmid RM, Bergmann L, Munzert G (2003) Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activation. Exp Hematol 31(6):504–511
118. Kishi K, Petersen S, Petersen C et al (2000) Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res 60(5):1326–1331
119. Kobayashi H, Boelte KC, Lin PC (2007) Endothelial cell adhesion molecules and cancer progression. Curr Med Chem 14(4):377–386. doi:10.2174/092986707779941032
120. Kojima M, Morisaki T, Sasaki N et al (2004) Increased nuclear factor-kappa B activation in human colorectal carcinoma and its correlation with tumor progression. Anticancer Res 24(2B):675–681
121. Kornmann M, Arber N, Korc M (1998) Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. J Clin Invest 101(2):344–352. doi:10.1172/Jci1323
122. Kornmann M, Danenberg KD, Arber N, Beger HG, Danenberg PV, Korc M (1999) Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes. Cancer Res 59(14):3505–3511
123. Krappmann D, Wegener E, Sunami Y et al (2004) The I kappa B kinase complex and NF-kappa B act as master regulators of lipopolysaccharide-induced gene expression and control subordinate activation of AP-1. Mol Cell Biol 24(14):6488–6500. doi:10.1128/Mcb.24.14.6488-6500.2004
124. Kumar A, Takada Y, Boriek AM, Aggarwal BB (2004) Nuclear factor-kappa B: its role in health and disease. J Mol Med 82(7):434–448. doi:10.1007/s00109-004-0555-y
125. Kyle RA, Rajkumar SV (2004) Multiple myeloma. N Engl J Med 351(18):1860–1873. doi:10.1056/NEJMra041875
126. LaCasse EC, Baird S, Korneluk RG, MacKenzie AE (1998) The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17(25):3247–3259
127. LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG (2008) IAP-targeted therapies for cancer. Oncogene 27(48):6252–6275. doi:10.1038/Onc.2008.302
128. Lam LT, Davis RE, Pierce J et al (2005) Small molecule inhibitors of I kappa B kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 11(1):28–40
129. Landesman-Bollag E, Romieu-Mourez R, Song DH, Sonenshein GE, Cardiff RD, Seldin DC (2001) Protein kinase CK2 in mammary gland tumorigenesis. Oncogene 20(25):3247–3257. doi:10.1038/sj.onc.1204411
130. Le Page C, Koumakpayi IH, Lessard L, Mes-Masson AM, Saad F (2005) EGFR and Her-2 regulate the constitutive activation of NF-kappaB in PC-3 prostate cancer cells. Prostate 65(2):130–140. doi:10.1002/pros.20234
131. Lee H, Herrmann A, Deng JH et al (2009) Persistently activated Stat3 maintains constitutive NF-kappa B activity in tumors. Cancer Cell 15(4):283–293. doi:10.1016/j.ccr.2009.02.015
132. Levine L, Lucci JA, Pazdrak B et al (2003) Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells. Cancer Res 63(13):3495–3502
133. Li F, Sethi G (2010) Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta 1805(2):167–180. doi:10.1016/j.bbcan.2010.01.002
134. Li Q, Verma IM (2002) NF-kappaB regulation in the immune system. Nat Rev Immunol 2(10):725–734. doi:10.1038/nri910
135. Lind DS, Hochwald SN, Malaty J et al (2001) Nuclear factor-kappa B is upregulated in colorectal cancer. Surgery 130(2):363–369. doi:10.1067/msy.2001.116672
136. Liu HL, Lo CR, Czaja MJ (2002) NF-kappa B inhibition sensitizes hepatocytes to TNF-induced apoptosis through a sustained activation of JNK and c-Jun. Hepatology 35(4):772–778. doi:10.1053/jhep.2002.32534
137. Loercher A, Lee TL, Ricker JL et al (2004) Nuclear factor-kappa B is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res 64(18):6511–6523. doi:10.1158/0008-5472.Can-04-0852
138. Lopez-Novoa JM, Nieto MA (2009) Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol Med 1(6–7):303–314. doi:10.1002/emmm.200900043
139. Lu CD, Altieri DC, Tanigawa N (1998) Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 58(9):1808–1812
140. Luo JL, Maeda S, Hsu LC, Yagita H, Karin M (2004) Inhibition of NF-kappa B in cancer cells converts inflammation-induced tumor growth mediated by TNF alpha to TRAIL-mediated tumor regression. Cancer Cell 6(3):297–305. doi:10.1016/j.ccr.2004.08.012
141. Luo JL, Tan W, Ricono JM et al (2007) Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature 446(7136):690–694. doi:10.1038/nature05656
142. Lyss G, Knorre A, Schmidt TJ, Pahl HL, Merfort I (1998) The anti-inflammatory sesquiterpene lactone helenalin inhibits the transcription factor NF-kappaB by directly targeting p65. J Biol Chem 273(50):33508–33516
143. Madrid LV, Wang CY, Guttridge DC, Schottelius AJG, Baldwin AS, Mayo MW (2000) Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappa B. Mol Cell Biol 20(5):1626–1638. doi:10.1128/Mcb.20.5.1626-1638.2000
144. Madrid LV, Mayo MW, Reuther JY, Baldwin AS (2001) Akt stimulates the transactivation potential of the RelA/p65 subunit of NF-kappa B through utilization of the I kappa B kinase and activation of the mitogen-activated protein kinase p38. J Biol Chem 276(22):18934–18940. doi:10.1074/jbc.M101103200
145. Maeda S, Kamata H, Luo JL, Leffert H, Karin M (2005) IKK beta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121(7):977–990. doi:10.1016/j.cell.2005.04.014
146. 2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester. J Immunol 168(6):2644–2651
147. Matsuoka M, Jeang KT (2007) Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 7(4):270–280. doi:10.1038/Nrc2111
148. Mayo MW, Wang CY, Cogswell PC et al (1997) Requirement of NF-kappa B activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science 278(5344):1812–1815. doi:10.1126/science.278.5344.1812
149. McGivern DR, Lemon SM (2011) Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. Oncogene 30(17):1969–1983. doi:10.1038/Onc.2010.594
150. Mishra A, Bharti AC, Varghese P, Saluja D, Das BC (2006) Differential expression and activation of NF-kappaB family proteins during oral carcinogenesis: role of high risk human papillomavirus infection. Int J Cancer 119(12):2840–2850. doi:10.1002/ijc.22262
151. Mita AC, Mita MM, Nawrocki ST, Giles FJ (2008) Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 14(16):5000–5005. doi:10.1158/1078-0432.Ccr-08-0746
152. Mitsiades N, Mitsiades CS, Poulaki V et al (2002a) Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 99(22):14374–14379. doi:10.1073/pnas.202445099
153. Mitsiades N, Mitsiades CS, Poulaki V et al (2002b) Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99(12):4525–4530
154. Molinolo AA, Amornphimoltham P, Squarize CH, Castilho RM, Patel V, Gutkind JS (2009) Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol 45(4–5):324–334. doi:10.1016/j.oraloncology.2008.07.011
155. Muller M, Morotti A, Ponzetto C (2002) Activation of NF-kappa B is essential for hepatocyte growth factor-mediated proliferation and tubulogenesis. Mol Cell Biol 22(4):1060–1072. doi:10.1128/Mcb.22.4.1060-1072.2002
156. Nakanishi C, Toi M (2005) Nuclear factor-kappa B inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5(4):297–309. doi:10.1038/Nrc1588
157. Nakano H, Nakajima A, Sakon-Komazawa S, Piao JH, Xue X, Okumura K (2006) Reactive oxygen species mediate crosstalk between NF-kappa B and JNK. Cell Death Differ 13(5):730–737. doi:10.1038/sj.cdd.4401830
158. Nakashima T, Clayman GL (2000) Antisense inhibition of cyclin D1 in human head and neck squamous cell carcinoma. Arch Otolaryngol 126(8):957–961
159. Nakata E, Mason KA, Hunter N et al (2004) Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitors. Int J Radiat Oncol 58(2):369–375. doi:10.1016/j.ijrobp.2003.09.061
160. Nakayama H, Ikebe T, Beppu M, Shirasuna K (2001) High expression levels of nuclear factor kappaB, IkappaB kinase alpha and Akt kinase in squamous cell carcinoma of the oral cavity. Cancer 92(12):3037–3044
161. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge GW Jr (1997) Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17(7):3629–3639
162. Nakshatri H, Rice SE, Bhat-Nakshatri P (2004) Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. Oncogene 23(44):7330–7344. doi:10.1038/sj.onc.1207995
163. Nam S, Smith DM, Dou QP (2001) Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem 276(16):13322–13330. doi:10.1074/jbc.M004209200
164. Normanno N, De Luca A, Bianco C et al (2006) Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366(1):2–16. doi:10.1016/j.gene.2005.10.018
165. Olsen LS, Hjarnaa PJV, Latini S et al (2004) Anticancer agent CHS 828 suppresses nuclear factor-kappa B activity in cancer cells through downregulation of ikk activity. Int J Cancer 111(2):198–205. doi:10.1002/Ijc.20255
166. Ondrey FG, Dong G, Sunwoo J et al (1999) Constitutive activation of transcription factors NF-kappa B, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines. Mol Carcinogen 26(2):119–129. doi:10.1002/(Sici)1098-2744(199910)26:2<119:Aid-Mc6>3.0.Co;2-N
167. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB (1999) NF-kappa B activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401(6748):82–85
168. Palayoor ST, Youmell MY, Calderwood SK, Coleman CN, Price BD (1999) Constitutive activation of I kappa B kinase alpha and NF-kappa B in prostate cancer cells is inhibited by ibuprofen. Oncogene 18(51):7389–7394. doi:10.1038/sj.onc.1203160
169. Papa S, Zazzeroni F, Pham CG, Bubici C, Franzoso G (2004) Linking JNK signaling to NF-kappa B: a key to survival. J Cell Sci 117(22):5197–5208. doi:10.1242/Jcs.01483
170. Papa S, Bubici C, Zazzeroni F et al (2006) The NF-kappa B-mediated control of the JNK cascade in the antagonism of programmed cell death in health and disease. Cell Death Differ 13(5):712–729. doi:10.1038/sj.cdd.4401865
171. Park KJ, Krishnan V, O’Malley BW, Yamamoto Y, Gaynor RB (2005) Formation of an IKK alpha-dependent transcription complex is required for estrogen receptor-mediated gene activation. Mol Cell 18(1):71–82. doi:10.1016/j.molcel.2005.03.006
172. Perkins ND (1997) Achieving transcriptional specificity with NF-kappa B. Int J Biochem Cell B 29(12):1433–1448. doi:10.1016/S1357-2725(97)00088-5
173. Perkins ND (2004) NF-kappa B: tumor promoter or suppressor? Trends Cell Biol 14(2):64–69. doi:10.1016/j.tcb.2003.12.004
174. Perkins ND (2007) Integrating cell-signalling pathways with NF-kappa B and IKK function. Nat Rev Mol Cell Bio 8(1):49–62. doi:10.1038/Nrm2083
175. Petersen C, Petersen S, Milas L, Lang FF, Tofilon PJ (2000) Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. Clin Cancer Res 6(6):2513–2520
176. Pham CG, Bubici C, Zazzeroni F et al (2004) Ferritin heavy chain upregulation by NF-kappa B inhibits TNF alpha-induced apoptosis by suppressing reactive oxygen species. Cell 119(4):529–542. doi:10.1016/j.cell.2004.10.017
177. Pianetti S, Arsura M, Romieu-Mourez R, Coffey RJ, Sonenshein GE (2001) Her-2/neu overexpression induces NF-kappa B via a PI3-kinase/Akt pathway involving calpain-mediated degradation of I kappa-B-alpha that can be inhibited by the tumor suppressor PTEN. Oncogene 20(11):1287–1299. doi:10.1038/sj.onc.1204257
178. Pikarsky E, Porat RM, Stein I et al (2004) NF-kappa B functions as a tumour promoter in inflammation-associated cancer. Nature 431(7007):461–466. doi:10.1038/Nature02924
179. Plummer SM, Holloway KA, Manson MM et al (1999) Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene 18(44):6013–6020. doi:10.1038/sj.onc.1202980
180. Poligone B, Baldwin AS (2001) Positive and negative regulation of NF-kappa B by COX-2-Roles of different prostaglandins. J Biol Chem 276(42):38658–38664. doi:10.1074/jbc.M106599200
181. Qiao L, Zhang H, Yu J et al (2006) Constitutive activation of NF-kappaB in human hepatocellular carcinoma: evidence of a cytoprotective role. Hum Gene Ther 17(3):280–290. doi:10.1089/hum.2006.17.280
182. Ravaud A, Cerny T, Terret C et al (2005) Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study. Eur J Cancer 41(5):702–707. doi:10.1016/j.ejca.2004.12.023
183. Ray A, Prefontaine KE (1994) Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci USA 91(2):752–756
184. Rayet B, Gelinas C (1999) Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18(49):6938–6947. doi:10.1038/sj.onc.1203221
185. Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin AS Jr (1998) A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev 12(7):968–981
186. Richardson PG, Barlogie B, Berenson J et al (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. New Engl J Med 348(26):2609–2617. doi:10.1056/Nejmoa030288
187. Ripple MO, Henry WF, Schwarze SR, Wilding G, Weindruch R (1999) Effect of antioxidants on androgen-induced AP-1 and NF-kappa B DNA-binding activity in prostate carcinoma cells. J Natl Cancer I 91(14):1227–1232. doi:10.1093/jnci/91.14.1227
188. Rius J, Guma M, Schachtrup C et al (2008) NF-kappa B links innate immunity to the hypoxic response through transcriptional regulation of HIF-1 alpha. Nature 453(7196):807-U9. doi:10.1038/Nature06905
189. Romashkova JA, Makarov SS (1999) NF-kappa B is a target of AKT in anti-apoptotic PDGF signalling. Nature 401(6748):86–90
190. Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Traish AM, Mercurio F, Sonenshein GE (2001) Roles of IKK kinases and protein kinase CK2 in activation of nuclear factor-kappa B in breast cancer. Cancer Res 61(9):3810–3818
191. Romieu-Mourez R, Kim DW, Shin SM et al (2003) Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors. Mol Cell Biol 23(16):5738–5754
192. Ross JS, Kallakury BVS, Sheehan CE et al (2004) Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-kappa B immunoreactivity with disease recurrence. Clin Cancer Res 10(7):2466–2472. doi:10.1158/1078-0432.Ccr-0543-3
193. Russo SM, Tepper JE, Baldwin AS et al (2001) Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappa B. Int J Radiat Oncol 50(1):183–193. doi:10.1016/S0360-3016(01)01446-8
194. Sarela AI, Macadam RCA, Farmery SM, Markham AF, Guillou PJ (2000) Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 46(5):645–650. doi:10.1136/Gut.46.5.645
195. Sarkar FH, Li YW, Wang ZW, Kong DJ (2008) NF-kappa B signaling pathway and its therapeutic implications in human diseases. Int Rev Immunol 27(5):293–319. doi:10.1080/08830180802276179
196. Sato Y, Kato J, Takimoto R et al (2006) Hepatitis C virus core protein promotes proliferation of human hepatoma cells through enhancement of transforming growth factor alpha expression via activation of nuclear factor-kappa B. Gut 55(12):1801–1808. doi:10.1136/gut.2005.070417
197. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr (1995) Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 270(5234):283–286
198. Schramek D, Leibbrandt A, Sigl V et al (2010) Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468(7320):98–102. doi:10.1038/Nature09387
199. Schreinemachers DM, Everson RB (1994) Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5(2):138–146
200. Schrump DS, Chen A, Consoli U (1996) Inhibition of lung cancer proliferation by antisense cyclin D. Cancer Gene Ther 3(2):131–135
201. Sen R, Baltimore D (1986) Multiple Nuclear Factors Interact with the Immunoglobulin Enhancer Sequences. Cell 46(5):705–716. doi:10.1016/0092-8674(86)90346-6
202. Senftleben U, Cao YX, Xiao GT et al (2001) Activation by IKK alpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 293(5534):1495–1499. doi:10.1126/science.1062677
203. Sethi G, Tergaonkar V (2009) Potential pharmacological control of the NF-kappa B pathway. Trends Pharmacol Sci 30(6):313–321. doi:10.1016/j.tips.2009.03.004
204. Sethi G, Ahn KS, Chaturvedi MM, Aggarwal BB (2007) Epidermal growth factor (EGF) activates nuclear factor-kappa B through I kappa B alpha kinase-independent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of I kappa B alpha. Oncogene 26(52):7324–7332. doi:10.1038/sj.onc.1210544
205. Sethi G, Shanmugam MK, Ramachandran L, Kumar AP, Tergaonkar V (2012) Multifaceted link between cancer and inflammation. Biosci Rep 32(1):1–15. doi:10.1042/Bsr20100136
206. Shen HM, Tergaonkar V (2009) NF kappa B signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis 14(4):348–363. doi:10.1007/s10495-009-0315-0
207. Sherr CJ (1996) Cancer cell cycles. Science 274(5293):1672–1677. doi:10.1126/science.274.5293.1672
208. Shishodia S, Aggarwal BB (2004) Nuclear factor-KB: a friend or a foe in cancer? Biochem Pharmacol 68(6):1071–1080. doi:10.1016/j.bcp.2004.04.026
209. Shrivastava A, Manna SK, Ray R, Aggarwal BB (1998) Ectopic expression of hepatitis C virus core protein differentially regulates nuclear transcription factors. J Virol 72(12):9722–9728
210. Shukla S, MacLennan GT, Fu PF et al (2004) Nuclear factor-kappa B/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia 6(4):390–400. doi:10.1593/Neo.04112
211. Shukla S, Maclennan GT, Marengo SR, Resnick MI, Gupta S (2005) Constitutive activation of P I3 K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model. Prostate 64(3):224–239. doi:10.1002/pros.20217
212. Singh S, Shi Q, Bailey ST et al (2007) Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer. Mol Cancer Ther 6(7):1973–1982. doi:10.1158/1535-7163.MCT-07-0063
213. Singhal S, Mehta J, Desikan R et al (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341(21):1565–1571. doi:10.1056/NEJM199911183412102
214. Smith WL, DeWitt DL, Garavito RM (2000) Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69:145–182. doi:10.1146/annurev.biochem.69.1.145
215. Sovak MA, Bellas RE, Kim DW et al (1997) Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 100(12):2952–2960. doi:10.1172/JCI119848
216. Staudt LM (2010) Oncogenic activation of NF-kappa B. Csh Perspect Biol. doi:10.1101/cshperspect.a000109
217. Stehlik C, de Martin R, Kumabashiri I, Schmid JA, Binder BR, Lipp J (1998) Nuclear factor (NF)-kappa B-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis. J Exp Med 188(1):211–216. doi:10.1084/jem.188.1.211
218. Stein B, Baldwin AS (1993) Distinct Mechanisms for Regulation of the Interleukin-8 Gene Involve Synergism and Cooperativity between C/Ebp and Nf-Kappa-B. Mol Cell Biol 13(11):7191–7198
219. Stein B, Baldwin AS, Ballard DW, Greene WC, Angel P, Herrlich P (1993) Cross-coupling of the Nf-Theta-B P65 and Fos Jun transcription factors produces potentiated biological function. EMBO J 12(10):3879–3891
220. Subbaramaiah K, Hart JC, Norton L, Dannenberg AJ (2000) Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2—evidence for involvement of ERK1/2 and p38 mitogen-activated protein kinase pathways. J Biol Chem 275(20):14838–14845. doi:10.1074/jbc.275.20.14838
221. Subbaramaiah K, Marmo TP, Dixon DA, Dannenberg AJ (2003) Regulation of cyclooxgenase-2 mRNA stability by taxanes—evidence for involvement of p38, MAPKAPK-2, and HuR. J Biol Chem 278(39):37637–37647. doi:10.1074/jbc.M301481200
222. Suh J, Payvandi F, Edelstein LC et al (2002) Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate 52(3):183–200. doi:10.1002/pros.10082
223. Surh YJ (2003) Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3(10):768–780. doi:10.1038/nrc1189
224. Surh YJ, Chun KS, Cha HH et al (2001) Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res Fundam Mol M 480:243–268. doi:10.1016/S0027-5107(01)00183-X
225. Tai DI, Tsai SL, Chang YH et al (2000) Constitutive activation of nuclear factor kappa B in hepatocellular carcinoma. Cancer 89(11):2274–2281. doi:10.1002/1097-0142(20001201)89:11<2274:Aid-Cncr16>3.3.Co;2-U
226. Tak PP, Firestein GS (2001) NF-kappa B: a key role in inflammatory diseases. J Clin Invest 107(1):7–11. doi:10.1172/Jci11830
227. Takada Y, Aggarwal BB (2004) Flavopiridol inhibits NF-kappa B activation induced by various carcinogens and inflammatory agents through inhibition of I kappa B alpha kinase and p65 phosphorylation—abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9. J Biol Chem 279(6):4750–4759. doi:10.1074/jbc.M304546200
228. Takada Y, Bhardwaj A, Potdar P, Aggarwal BB (2004) Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 23(57):9247–9258. doi:10.1038/sj.onc.1208169
229. Tamm I, Wang Y, Sausville E et al (1998) IAP-family protein Survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58(23):5315–5320
230. Tan W, Zhang WZ, Strasner A et al (2011) Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470(7335):548–553. doi:10.1038/Nature09707
231. Tang GL, Minemoto Y, Dibling B et al (2001) Inhibition of JNK activation through NF-kappa B target genes. Nature 414(6861):313–317. doi:10.1038/35104568
232. Terakado N, Shintani S, Yano JY et al (2004) Overexpression of cyclooxygenase-2 is associated with radioresistance in oral squamous cell carcinoma. Oral Oncol 40(4):383–389. doi:10.1016/j.oraloncology.2003.09.005
233. Tergaonkar V (2006) NF kappa B pathway: a good signaling paradigm and therapeutic target. Int J Biochem Cell B 38(10):1647–1653. doi:10.1016/j.biocel.2006.03.023
234. Terzic J, Grivennikov S, Karin E, Karin M (2010) Inflammation and Colon Cancer. Gastroenterology 138(6):2101-U119. doi:10.1053/j.gastro.2010.01.058
235. Trifan OC, Durham WF, Salazar VS et al (2002) Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res 62(20):5778–5784
236. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93(5):705–716. doi:10.1016/S0092-8674(00)81433-6
237. Vallabhapurapu S, Karin M (2009) Regulation and function of NF-kappa B transcription factors in the immune system. Annu Rev Immunol 27:693–733. doi:10.1146/annurev.immunol.021908.132641
238. Van Waes C (2007) Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res 13(4):1076–1082. doi:10.1158/1078-0432.CCR-06-2221
239. Viatour P, Merville MP, Bours V, Chariot A (2005) Phosphorylation of NF-kappa B and I kappa B proteins: implications in cancer and inflammation. Trends Biochem Sci 30(1):43–52. doi:10.1016/j.tiba.2004.11.009
240. Voorhees PM, Orlowski RZ (2006) The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol 46:189–213. doi:10.1146/annurev.pharmtox.46.120604.141300
241. Wagner EF, Nebreda AR (2009) Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9(8):537–549. doi:10.1038/Nrc2694
242. Wang D, DuBois RN (2006) Prostaglandins and cancer. Gut 55(1):115–122. doi:10.1136/gut.2004.047100
243. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS (1998) NF-kappa B antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281(5383):1680–1683. doi:10.1126/science.281.5383.1680
244. Wang CY, Guttridge DC, Mayo MW, Baldwin AS (1999) NF-kappa B induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 19(9):5923–5929
245. Wang ZW, Zhang YX, Banerjee S, Li YW, Sarkar FH (2006) Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer 106(11):2503–2513. doi:10.1002/Cncr.21904
246. Wang F, Arun P, Friedman J, Chen Z, Van Waes C (2009) Current and potential inflammation targeted therapies in head and neck cancer. Curr Opin Pharmacol 9(4):389–395. doi:10.1016/j.coph.2009.06.005
247. Waris G, Livolsi A, Imbert V, Peyron JF, Siddiqui A (2003) Hepatitis C virus NS5A and subgenomic replicon activate NF-kappa B via tyrosine phosphorylation of I kappa B alpha and its degradation by calpain protease. J Biol Chem 278(42):40778–40787. doi:10.1074/jbc.M303248200
248. Westerheide SD, Mayo MW, Anest V, Hanson JL, Baldwin AS (2001) The putative oncoprotein Bcl-3 induces cyclin d1 to stimulate G(1) transition. Mol Cell Biol 21(24):8428–8436. doi:10.1128/Mcb.21.24.8428-8436.2001
249. Wolf JS, Chen Z, Dong G et al (2001) IL (interleukin)-1alpha promotes nuclear factor-kappaB and AP-1-induced IL-8 expression, cell survival, and proliferation in head and neck squamous cell carcinomas. Clin Cancer Res 7(6):1812–1820
250. Wong ET, Tergaonkar V (2009) Roles of NF-kappa B in health and disease: mechanisms and therapeutic potential. Clin Sci 116(5–6):451–465. doi:10.1042/Cs20080502
251. Xia CL, Cheshire JK, Patel H, Woo P (1997) Cross-talk between transcription factors NF-kappa B and C/EBP in the transcriptional regulation of genes. Int J Biochem Cell B 29(12):1525–1539. doi:10.1016/S1357-2725(97)00083-6
252. Xia YF, Ye BQ, Li YD et al (2004) Andrographolide attenuates inflammation by inhibition of NF-kappa B activation through covalent modification of reduced cysteine 62 of p50. J Immunol 173(6):4207–4217
253. Yamamoto K, Arakawa T, Ueda N, Yamamoto S (1995) Transcriptional roles of nuclear factor kappa B and nuclear factor-interleukin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J Biol Chem 270(52):31315–31320
254. Yamamoto Y, Yin MJ, Lin KM, Gaynor RB (1999) Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem 274(38):27307–27314
255. Yamaoka S, Inoue H, Sakurai M et al (1996) Constitutive activation of NF-kappa B is essential for transformation of rat fibroblasts by the human T-cell leukemia virus type I Tax protein. EMBO J 15(4):873–887
256. Yang JM, Amiri KI, Burke JR, Schmid JA, Richmond A (2006) BMS-345541 targets inhibitor of kappa B kinase and induces apoptosis in melanoma: involvement of nuclear factor kappa B and mitochondria pathways. Clin Cancer Res 12(3):950–960. doi:10.1158/1078-0432.Ccr-05-1220
257. Yarden Y (2001) The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 37:S3–S8
258. Yeung F, Hoberg JE, Ramsey CS et al (2004) Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 23(12):2369–2380. doi:10.1038/sj.emboj.7600244
259. Yin MJ, Yamamoto Y, Gaynor RB (1998) The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396(6706):77–80. doi:10.1038/23948
260. Yoshida S, Ono M, Shono T et al (1997) Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 17(7):4015–4023
261. Young LS, Rickinson AB (2004) Epstein-Barr virus: 40 years on. Nat Rev Cancer 4(10):757–768. doi:10.1038/Nrc1452
262. Yu HG, Yu LL, Yang YN et al (2003) Increased expression of RelA/nuclear factor-kappa B protein correlates with colorectal tumorigenesis. Oncology-Basel 65(1):37–45. doi:10.1159/000071203
263. Yu M, Yeh J, Van Waes C (2006) Protein kinase casein kinase 2 mediates inhibitor-kappa B kinase and aberrant nuclear factor-kappa B activation by serum factor(s) in head and neck squamous carcinoma cells. Cancer Res 66(13):6722–6731. doi:10.1158/0008-5472.Can-05-3758
264. Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9(11):798–809. doi:10.1038/Nrc2734
265. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM (2004) Cyclooxygenases in cancer: progress and perspective. Cancer Lett 215(1):1–20. doi:10.1016/j.canlet.2004.06.014
266. Zhang PL, Pellitteri PK, Law A et al (2005) Overexpression of phosphorylated nuclear factor-kappa B in tonsillar squamous cell carcinoma and high-grade dysplasia is associated with poor prognosis. Mod Pathol 18(7):924–932. doi:10.1038/modpathol.3800372
267. Zhang LY, Altuwaijri S, Deng FM et al (2009) NF-kappa B regulates androgen receptor expression and prostate cancer growth. Am J Pathol 175(2):489–499. doi:10.2353/ajpath.2009.080727
268. Zhou P, Jiang W, Zhang YJ et al (1995) Antisense to Cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer-cells. Oncogene 11(3):571–580
269. Zhou BP, Hu MC, Miller SA et al (2000) HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem 275(11):8027–8031
270. Zong WX, Edelstein LC, Chen CL, Bash J, Gelinas C (1999) The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappa B that blocks TNF alpha-induced apoptosis. Genes Dev 13(4):382–387. doi:10.1101/Gad.13.4.382